Änderungen

Die US-amerikanische Aufsichtsbehörde FDA warnte am 10. Mai 2012 in einem "alert" mit dem Titel "FDA issues alert on potential dangers of unproven treatment for multiple sclerosis" vor dem so genannten CCSVI-"liberation treatment".<ref>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm303538.htm</ref>

Die US-amerikanische Aufsichtsbehörde FDA warnte am 10. Mai 2012 in einem "alert" mit dem Titel "FDA issues alert on potential dangers of unproven treatment for multiple sclerosis" vor dem so genannten CCSVI-"liberation treatment".<ref>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm303538.htm</ref>

Ein Cochrane-review (CD009903/MS) von August 2018 "The technique popularly known as 'liberation procedure' for treatment of venous stenoses (CCSVI) in the brain of people with MS" kommt zu einem abschliessenden negativen Urteil zum Liberation Treatment und empfiehl auch keine weiteren Studien zum Thema:

Ein Cochrane-review (CD009903/MS) von August 2018 "The technique popularly known as 'liberation procedure' for treatment of venous stenoses (CCSVI) in the brain of people with MS" kommt zu einem abschliessenden negativen Urteil zum Liberation Treatment und empfiehlt auch keine weiteren Studien zum Thema:

:''..What hat did we do? We reviewed three studies (238 participants) which compared PTA with sham-PTA in participants with MS and CCSVI.<br>What did we find? We found that venous PTA did not provide benefit on disability, physical or cognitive functions, relapses, or quality of life. No serious adverse events attributable to venography or venous PTA occurred.<br>Conclusions Venous PTA has proven to be a safe but ineffective intervention and cannot be recommended in patients with MS. All trials that were ongoing were either terminated or withdrawn, so this updated review is conclusive. No further randomised clinical studies are needed..''<ref>https://www.cochrane.org/CD009903/MS_technique-popularly-known-liberation-procedure-treatment-venous-stenoses-ccsvi-brain-people-ms</ref>

:''..What hat did we do? We reviewed three studies (238 participants) which compared PTA with sham-PTA in participants with MS and CCSVI.<br>What did we find? We found that venous PTA did not provide benefit on disability, physical or cognitive functions, relapses, or quality of life. No serious adverse events attributable to venography or venous PTA occurred.<br>Conclusions Venous PTA has proven to be a safe but ineffective intervention and cannot be recommended in patients with MS. All trials that were ongoing were either terminated or withdrawn, so this updated review is conclusive. No further randomised clinical studies are needed..''<ref>https://www.cochrane.org/CD009903/MS_technique-popularly-known-liberation-procedure-treatment-venous-stenoses-ccsvi-brain-people-ms</ref>

==CCSVI==

==CCSVI==